Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis BThe purpose of this study is to evaluate the safety and efficacy of tenofovir alafenamide (TAF) compared to that of tenofovir disoproxil fumarate (TDF) in treatment naive and experienced adult subjects with chronic hepatitis B virus (HBV) infection, as determined by the achievement of HBV DNA < Principal Investigator Peter W.C. KwanBody Locations and Systems Hepatitis BArea VancouverAge 18 and above
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis BThe purpose of this study is to evaluate the safety and efficacy of tenofovir alafenamide (TAF) compared to that of tenofovir disoproxil fumarate (TDF) in treatment naive and experienced adult subjects with chronic hepatitis B virus (HBV) infection, as determined by the achievement of HBV DNA < Principal Investigator Peter W.C. KwanBody Locations and Systems Hepatitis BArea VancouverAge 18 and above
Safety and Efficacy of GS-9620 for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed SubjectsThis study will evaluate the safety, tolerability, and efficacy of GS-9620 in virologically suppressed adults with chronic hepatitis B virus (HBV) infection who are currently being treated with oral antivirals (OAV). Participants will be randomized in 3 sequential cohorts. Principal Investigator Eric M. YoshidaBody Locations and Systems Hepatitis BArea VancouverAge 18-65
B and Who Are Currently Not on Treatment…This study is to evaluate the safety, tolerability, and efficacy of GS-4774 in adults with chronic hepatitis B infection (CHB) and who are currently not on treatment. Participants will be randomized to receive tenofovir disoproxil fumarate (TDF) alone or GS-4774 plus TDF for 20 weeks. Principal Investigator Eric M. YoshidaBody Locations and Systems Hepatitis BArea VancouverAge 18 and above
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay (HBVQuant)This non-interventional clinical study will be conducted to prospectively collect serial plasma samples from subjects with chronic HBV infection who are initiating antiviral therapy. Principal Investigator Peter W.C. KwanBody Locations and Systems Hepatitis BArea VancouverAge 18 and above
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B InfectionThis study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB). Principal Investigator Peter W.C. KwanBody Locations and Systems Hepatitis BArea VancouverAge 18 and above
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV (ACHEIVE)This is a Phase 2, open-label,randomized, multiple dose, varied administration regimen study with 2 parts (Parts A and B) in Subjects Infected with Chronic Hepatitis B Virus Principal Investigator Eric M. YoshidaBody Locations and Systems Hepatitis BArea VancouverAge 18-70
